Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2012OC065 Principal Investigator Miller, Weston
Phase NA
Age Group Both Scope Local
Title MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
Objective This is a treatment guideline to allow routine clinical data to be collected and maintained in OnCore and the University Of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.
Treatment This regimen, consisting of busulfan, fludarabine, and low dose total body irradiation (TBI), is designed to promote engraftment in patients with non-malignant diseases (NMD), and in rare cases with malignant diseases, who failed to achieve an acceptable level of donor-derived engraftment following a previous allogeneic HCT,including rare patients who may remain aplastic.
Description This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in patients with non-malignant diseases and, in rare cases, with malignant diseases.
Key Eligibility Diagnosis of any disease for which a second or greater hematopoietic stem cell transplant is needed due to insufficient donor chimerism following hematopoietic recovery after previous HSCT.
Applicable Disease Sites Acute Lymphocytic Leukemia (ALL)
Acute myeloid leukemia (AML)
Brain and Nervous System
Central Nervous System
Chronic myeloid leukemia (CML)
Hematologic Malignancies
Hemoglobinopathies
Hodgkin's Lymphoma
Juvenile myelomonocytic leukemia (JMML)
Leukemia
Lymphoid Leukemia
Metabolic Disorders
Myelodysplastic syndromes (MDS)
Myeloid and Monocytic Leukemia
Myeloproliferative diseases (MPD)
Non-Hodgkin's Lymphoma
Other
Therapies Involved Blood and Marrow Transplant
Drugs Involved BUSULFAN (MYLERAN)
FLUDARABINE (FLUDARA)
Total Body irradiation (TBI)
Status Open
Participating Institutions Masonic Cancer Center
Detailed Eligibility Must be no more than 55 years of age and have appropriate donor availability. Must be able to tolerate administration of total body irradiation. Women who are pregnant or nursing are not eligible. A signed informed consent and HIPAA authorization are required.
Treatment Type Other
Contact Teresa Kivisto Phone:612-273-2924
Email:tkivis1@fairview.org